Battling the two-headed dragon of prostate cancer targeted therapy

Scott Wilkinson; Adam G Sowalsky

doi:10.1080/23723556.2020.1745037

Battling the two-headed dragon of prostate cancer targeted therapy

Mol Cell Oncol. 2020 Apr 14;7(4):1745037. doi: 10.1080/23723556.2020.1745037. eCollection 2020.

Authors

Scott Wilkinson¹, Adam G Sowalsky¹

Affiliation

¹ Laboratory of Genitourinary Cancer Pathogenesis, National Cancer Institute, Bethesda, MD, USA.

Abstract

Neoadjuvant intense androgen deprivation therapy for high-risk localized prostate cancer is an emerging but unproven treatment paradigm that is hoped to delay or prevent disease recurrence. We found that a patient enrolled in a clinical trial harbored two completely independent prostate cancers that responded differently to this therapy.

Keywords: Prostate cancer; enzalutamide; intense neoadjuvant therapy; non-response; response.

Grants and funding

This work was supported by the Prostate Cancer Foundation (Young Investigator Awards to S.W. and A.G.S.), the Department of Defense CDMRP Prostate Cancer Research Program (Early Investigator Research Award [W81XWH-19-1-0712] to S.W. and Impact Award [W81XWH-15-1-0710] to A.G.S.) and the Intramural Research Program of the NIH, National Cancer Institute.